Anti-Infective Drugs Global Market Report 2018

1. Anti-Infective Drugs Global Market Report 2018 Including: Antivirals; Antibiotics; Antifungals; Others (Antihelmethic, Antiprotozoal) Covering: Gilead, Merck & Co., GlaxosmithKline, Bristol-Myers Squibb Company, Johnson & Johnson Feb 2018

2. Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information. • Identify growth segments for investment. • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market. • Create regional and country strategies on the basis of local data and analysis. • Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors. • Develop strategies based on likely future developments. • Utilize the relationships between key data sets for superior strategizing. • Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market. • Report will be updated with the latest data and delivered to you within 3-5 working days of order. Scope Markets Covered: Antivirals; Antibiotics; Antifungals; Others (Antihelmethic, Antiprotozoal) Companies Mentioned: Gilead, Merck & Co., GlaxosmithKline, Bristol-Myers Squibb Company, Johnson & Johnson Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia. Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast. Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Anti-Infective Drugs Indicators Comparison. Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments. Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

3. Anti Anti- -Infective Drugs Infective Drugs Market Characteristics Characteristics Market Infectious diseases are disorders caused by several pathogenic organisms such as bacteria, viruses, fungi or parasites. These diseases can be transmitted or spread from one person to another through direct contact or indirect contact. Anti- infective drugs are used to treat or prevent these infectious diseases by inhibiting the spread of an infectious agent (static) or by killing the infectious agent (cidal). The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing. Based on the target pathogenic organism, anti-infective drugs are classified as follows – Antiviral Drugs are used to Antibacterial Drugs/Antibiotic Drugs are used to treat or Antifungal Drugs are used to Antiparasitic Drugs are used to Antiprotozoal Drugs are used to Antimalarial Drugs are used to treat or Antihelminthic Drugs are used to Ectoparasiticide Drugs are used to In this report market value is defined as the revenues organizations earn by selling their goods and services within the specified market, based on the price at which they sell. Only goods and services traded between entities are included.

4. The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.

5. Anti Anti- -Infective Drugs Infective Drugs Market Historic Growth Historic Growth Market The global anti-infective drugs market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%. The chart and table below shows the year-on-year growth of the global anti- infective drugs market during 2013 – 2017. Drivers of the Market: Restraints on the Market:

6. Anti Anti- -Infective Drugs Infective Drugs Market Forecast Growth Forecast Growth Market The global anti-infective drugs market is expected to grow from $XX billion in 2017 to $132.6 billion in 2021 at a compound annual growth rate (CAGR) of XX%. This growth is mainly due to the growing infectious diseases caused by bacteria, viruses, fungi and the expected increase in global healthcare expenditure. According to the Institute for Health Metrics and Evaluation (IHME), global spending on healthcare is expected to increase to $18.28 trillion by 2040. The chart and table below shows the year-on-year growth of the global anti- infective drugs market during 2017 - 2021. Drivers of the Market: Restraints on the Market:

7. Anti Anti- -Infective Drugs Infective Drugs Market Segmentation Segmentation Market The chart and table below shows the split of the anti-infective drugs market in 2017. The total market value for anti-infective drugs was $X billion in 2017. The markets that are covered include Antivirals; Antibiotics; Antifungals; Others (Antihelmethic, Antiprotozoal). Antivirals was the X largest segment in the anti-infective drugs market with X% share of the market. The market value for the antivirals was $X billion in 2017. Antibiotics made up around X% share of the market. The market value for the antibiotics was $X billion in 2017.

8. Anti Anti- -Infective Drugs Infective Drugs Market Regional And Country Analysis Regional And Country Analysis Market The Asia Pacific was the largest region in the anti-infective drugs market in 2017, anti-infective drugs for $X billion or X% market share. North America was the x largest region anti-infective drugs for $X billion or X% market share. Western Europe was the x largest region anti-infective drugs for $X billion or X% market share.

9. Anti Anti- -Infective Drugs Infective Drugs Market Competitive Landscape Competitive Landscape Market The leading competitors in the global anti-infective drugs market are Gilead, Merck & Co., GlaxosmithKline, Bristol-Myers Squibb Company, Johnson & Johnson. The chart and table below displays the percentage market share of the top players in the anti-infective drugs market industry. Gilead generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Merck & Co. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. GlaxosmithKline generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Bristol-Myers Squibb Company generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year.

10. Johnson & Johnson generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Pfizer generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. AbbVie generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Novartis AG generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Bayer AG generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Otsuka generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Company Profile Gilead Overview Products and Services The company’s products for various diseases include – The HIV products include The Liver Diseases products include Gilead was the largest competitor in the anti-infective drugs market in 2017 with a 13.81% market share. Gilead is an American biopharmaceutical company that discovers, develops and commercializes therapeutics for areas such as cardiovascular and inflammation/respiratory hematology/oncology, human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection. The company was founded in 1987 and is headquartered in Foster City, California, United States. diseases,

11. Strategy Financial Performance Gilead’s Hepatitis C, HIV and Other products generated revenues of $XX billion in 2016, a XX% decrease from the previous year. The company had a market Merck & Co. Overview Products and Services Strategy Financial Performance GlaxosmithKline Overview Products and Services Strategy Financial Performance Bristol-Myers Squibb Company Overview Products and Services Strategy Financial Performance Johnson & Johnson Overview Products and Services Strategy Financial Performance The Cardiovascular products include The Inflammation/Respiratory products include Gilead’s growth strategy aims to focus on development of products for HIV, viral hepatitis and other diseases through collaborations with other companies, medical research institutions and